STERIS plc STE SPX
STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Profit CAGR of 36.1% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | STE STERIS plc SPX | 212.73 | 26.83 | $20.88B | 1.18% | 9.67% | 11.37% | 8.93% | 36.09% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 607.96M | 661.90M | 715.97M | 638.76M | 678.96M | 696.24M | 768.21M | 696.80M | 736.84M | 774.26M | 822.99M | 668.93M | 756.13M | 808.92M | 873.53M | 968.42M | 1.20B | 1.21B | 1.21B | 1.05B | 1.09B | 1.11B | 1.28B | 1.18B | 1.24B | 1.30B | 1.42B | 1.28B | - | 1.37B | 1.48B | 1.39B | 1.46B | 1.50B | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 760.20M | 839.32M | 763.10M | 814.40M | 840.70M | - |
| Gross Profit | 255.77M | 278.22M | 292.37M | 269.05M | 284.66M | 287.00M | 334.72M | 306.89M | 318.67M | 331.35M | 363.09M | 287.38M | 330.04M | 345.86M | 379.82M | 426.28M | 480.34M | 538.11M | 571.62M | 473.82M | 482.31M | 478.19M | 546.40M | 529.00M | 546.23M | 560.03M | 582.90M | 572.40M | - | 610.30M | 641.21M | 628.00M | 645.90M | 655.50M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 362.90M | 361.59M | 380.20M | 377.90M | 381.80M | - |
| Operating Income | - | - | - | 94.42M | 106.58M | 69.58M | - | 110.09M | 126.73M | 142.39M | - | 115.82M | 141.26M | 147.03M | - | 14.32M | 116.50M | 202.93M | - | 158.40M | -306.42M | 190.80M | - | 197.76M | 191.55M | 226.47M | - | 185.50M | - | 247.40M | 279.62M | 247.80M | 268.00M | 273.70M | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 373.70M | 336.77M | 367.20M | 389.70M | 394.70M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.10M | 17.11M | 15.90M | 14.90M | 14.90M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 228.70M | 197.31M | 231.90M | 253.10M | 257.80M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 55.40M | 50.45M | 53.90M | 60.60M | 63.50M | - |
| Net Income | 58.08M | 94.78M | 73.60M | 69.99M | 77.46M | 47.86M | 108.75M | 85.37M | 94.77M | 104.93M | 122.59M | 89.60M | 105.86M | 114.50M | 87.44M | -21.81M | 69.81M | 143.62M | 52.26M | 111.26M | -315.29M | 123.83M | 187.22M | 123.55M | 115.32M | 140.74M | -1.38M | 145.40M | - | 173.50M | 145.67M | 177.40M | 191.90M | 192.80M | - |
| Diluted EPS | 0.68 | 1.11 | 0.86 | 0.82 | 0.91 | 0.56 | 1.27 | 1.00 | 1.11 | 1.23 | 1.43 | 1.05 | 1.23 | 1.33 | 1.02 | -0.24 | 0.69 | 1.42 | 0.52 | 1.10 | -3.15 | 1.24 | 1.88 | 1.25 | 1.16 | 1.42 | -0.01 | 1.46 | - | - | 1.48 | 1.79 | 1.94 | 1.96 | 2.24 |
| R&D Expense | - | - | - | 16.22M | 15.77M | 15.17M | - | 15.59M | 16.25M | 16.49M | - | 16.23M | 16.14M | 16.44M | - | 18.19M | 18.83M | 24.82M | - | 24.75M | 24.93M | 25.51M | - | 24.69M | 26.27M | 25.25M | - | 25.60M | 27.00M | 27.40M | - | 26.40M | 28.20M | 29.50M | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.61B | 2.62B | 2.78B | 3.03B | 3.11B | 4.22B | 4.54B | 5.14B | 5.46B | - |
| Cost of Revenue | - | - | - | - | - | 2.34B | 2.56B | 2.92B | 3.06B | - |
| Gross Profit | 1.03B | 1.09B | 1.17B | 1.32B | 1.34B | 1.88B | 1.98B | 2.22B | 2.40B | - |
| Operating Expenses | - | - | - | - | - | 1.41B | 1.19B | 1.36B | 1.44B | - |
| Operating Income | 226.21M | 399.88M | 411.02M | 537.05M | 548.37M | 477.86M | 791.59M | 862.16M | 960.84M | - |
| EBITDA | - | - | - | - | - | 1.01B | 1.34B | 1.41B | 1.36B | - |
| Interest Expense | - | - | - | - | - | 89.49M | 110.83M | 144.35M | 86.26M | - |
| Pretax Income | - | - | - | - | - | 366.80M | 680.27M | 702.81M | 796.21M | - |
| Tax Provision | - | - | - | - | - | 82.34M | 124.07M | 149.53M | 184.65M | - |
| Net Income | 109.97M | 290.92M | 303.72M | 407.66M | 397.40M | 243.89M | 107.03M | 378.24M | 614.64M | - |
| Diluted EPS | 1.28 | 3.39 | 3.55 | 4.76 | 4.63 | - | 1.07 | 3.81 | 6.20 | 7.93 |
| R&D Expense | 59.40M | 60.78M | 63.04M | 65.55M | 66.33M | 86.66M | 98.48M | 103.68M | 107.65M | - |
Compounded Sales Growth
| 5 Years: | 8.93% |
| 1 Year: | 7.30% |
Compounded Profit Growth
| 5 Years: | 36.09% |
| 1 Year: | 52.20% |
Stock Price Performance
| 1 Year: | -12.59% |
| 6 Months: | -20.36% |
| 3 Months: | -15.70% |
| 1 Month: | +0.04% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 5.20B | 5.07B | 5.44B | 6.57B | 11.42B | 10.82B | 11.06B | 10.15B |
| Current Assets | - | - | - | - | - | - | 1.88B | 2.01B | 2.87B | 2.00B |
| Cash & Equivalents | 248.84M | 282.92M | 201.53M | 220.63M | 319.58M | 220.53M | 348.32M | 208.36M | 207.02M | 171.70M |
| Inventory | - | - | - | - | - | - | 575.00M | 604.41M | 674.53M | 581.33M |
| Receivables | - | - | - | - | - | - | 799.04M | 864.99M | 1.01B | 1.04B |
| Total Liabilities | - | - | 1.98B | 1.89B | 2.02B | 2.68B | 4.88B | 4.73B | 4.75B | 3.53B |
| Current Liabilities | - | - | 398.46M | 465.20M | 503.61M | 577.92M | 922.22M | 861.84M | 931.13M | 1.02B |
| Long Term Debt | - | - | 1.32B | 1.18B | 1.15B | 1.65B | 2.95B | 3.02B | 3.12B | 1.92B |
| Total Debt | - | - | - | - | - | - | 3.28B | 3.25B | 3.38B | 2.20B |
| Total Equity | - | - | 3.21B | 3.18B | 3.41B | 3.88B | 6.53B | 6.08B | 6.30B | 6.60B |
| Shares Outstanding | - | - | - | - | - | - | 100.07M | 98.63M | 98.88M | 98.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 424.09M | 457.63M | 539.50M | 590.56M | 689.64M | 684.81M | 756.95M | 973.27M | 1.15B |
| Investing Cash Flow | -104.25M | -203.83M | -213.22M | -319.74M | -1.15B | -666.56M | -383.33M | -887.36M | 388.77M |
| Financing Cash Flow | -267.10M | -356.18M | -294.79M | -163.15M | 345.62M | 115.83M | -498.72M | -85.19M | -1.57B |
| Capital Expenditure | -172.90M | -165.46M | -189.72M | -214.52M | -239.26M | -287.56M | -361.97M | -360.33M | -370.09M |
| Free Cash Flow | 251.19M | 292.18M | 349.79M | 376.04M | 450.38M | 397.25M | 394.98M | 612.95M | 778.00M |
| Net Change in Cash | - | - | - | - | - | 134.08M | -125.10M | 727.00K | -35.50M |
| Share Buybacks | 97.51M | 65.48M | 81.49M | 51.24M | 14.65M | 55.78M | 308.56M | 11.77M | 211.32M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 39.3% | 41.7% | 42.2% | 43.6% | 43.2% | 44.6% | 43.7% | 43.2% | 44.0% | - |
| Operating Margin % | 8.7% | 15.3% | 14.8% | 17.7% | 17.6% | 11.3% | 17.5% | 16.8% | 17.6% | - |
| Net Margin % | 4.2% | 11.1% | 10.9% | 13.5% | 12.8% | 5.8% | 2.4% | 7.4% | 11.3% | - |
| ROE % | - | 9.1% | 9.6% | 12.0% | 10.2% | 3.7% | 1.8% | 6.0% | 9.3% | - |
| ROCE % | - | 8.3% | 8.9% | 10.9% | 9.1% | 4.6% | 7.9% | 8.5% | 10.5% | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.20% | 9.03M | $1.92B |
| 2 | Vanguard Capital Management LLC | 6.49% | 6.37M | $1.35B |
| 3 | State Street Corporation | 5.09% | 4.99M | $1.06B |
| 4 | Vanguard Portfolio Management LLC | 5.05% | 4.95M | $1.05B |
| 5 | Morgan Stanley | 4.48% | 4.39M | $934.79M |
| 6 | Massachusetts Financial Services Co. | 4.09% | 4.01M | $853.12M |
| 7 | Wellington Management Group, LLP | 2.93% | 2.87M | $611.25M |
| 8 | Orbis Allan Gray Ltd | 2.64% | 2.59M | $551.59M |
| 9 | Geode Capital Management, LLC | 2.63% | 2.58M | $549.21M |
| 10 | Generation Investment Management LLP | 2.35% | 2.31M | $491.08M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for STE